nonclin
safeti
test
provid
evid
particular
vaccin
safe
administ
human
clinic
trial
conduct
prior
case
concurr
trial
anim
studi
afford
clinician
data
potenti
toxic
organ
organ
system
may
affect
result
vaccin
impur
contamin
compon
formul
interact
thereof
toxic
result
expect
immun
respons
vaccin
toxic
data
also
use
defin
dose
may
safe
administ
human
noobservedeffect
level
dose
toxicolog
relev
find
identifi
caveat
studi
vaccin
well
type
molecul
may
rare
subpopul
toxic
may
address
human
gener
anim
model
may
alway
reflect
might
observ
human
order
ensur
nonclin
studi
support
human
clinic
trial
vaccin
conduct
robust
consist
manner
across
industri
recogn
wide
accept
comprehens
guidelin
requir
nonclin
develop
guidelin
european
medicin
agenc
ema
guidelin
approv
well
unit
state
code
feder
regul
us
cfr
individu
countryspecif
compendia
least
mention
nonclin
studi
specif
vaccin
avail
mani
year
howev
inform
either
insuffici
detail
gear
toward
requir
lot
releas
ind
investig
new
drug
submiss
therefor
member
academia
industri
us
european
regulatori
agenc
conven
discuss
draft
first
world
health
organ
guidelin
nonclin
evalu
vaccin
guidelin
would
comprehens
document
provid
detail
item
anim
model
studi
design
dose
rout
iii
vaccin
administr
dose
schedul
endpoint
addit
would
includ
specif
method
evalu
addit
compon
vaccin
formul
adjuv
excipi
vaccin
administ
via
nonroutin
rout
administr
specif
type
vaccin
includ
combin
vaccin
guidelin
avail
wide
use
throughout
industri
gold
standard
design
nonclin
vaccin
program
addit
guidelin
mani
guidanc
document
also
avail
outlin
regulatori
expect
tradit
well
novel
type
vaccin
tabl
origin
ema
guidelin
still
effect
appli
vaccin
chines
japanes
guidanc
document
case
guidelin
also
detail
countryspecif
requir
guidanc
also
avail
provid
specif
detail
particular
vaccin
administ
pregnant
women
women
childbear
wcbp
women
childbear
potenti
potenti
adjuv
dna
viralvector
vaccin
combin
vaccin
addit
implement
routin
nonclin
evalu
vaccin
program
focus
safeti
vaccin
implement
vaccin
advers
event
report
system
vaer
postmarket
surveil
system
develop
center
diseas
control
cdc
us
food
drug
administr
fda
track
advers
event
occur
administr
uslicens
vaccin
vaccin
manufactur
also
awar
specif
countri
may
guidelin
outlin
expect
nonclin
evalu
vaccin
may
differ
significantli
ema
japan
china
guidelin
one
exampl
india
vaccin
consid
drug
nonclin
guidelin
tabl
result
toxicolog
studi
requir
vaccin
extens
challeng
design
compar
wellaccept
vaccinespecif
program
exampl
indian
guidanc
requir
studi
conduct
two
speci
use
two
rout
administr
eg
intramuscular
subcutan
dose
rang
identif
maximum
toler
dose
mtd
contrast
smallmolecul
drug
vaccin
metabol
via
enzym
multipl
speci
typic
requir
toxicolog
test
small
molecul
ensur
anim
model
repres
metabol
observ
human
need
addit
nonclin
immunogen
studi
typic
conduct
one
speci
would
allow
identif
speciesspecif
differ
would
need
evalu
toxicolog
perspect
given
rout
administr
vaccin
parenter
eg
intramuscular
subcutan
goal
induc
depot
effect
vaccin
antigen
retain
site
inject
may
suffici
opportun
interact
immun
system
singl
relev
rout
administr
ie
anticip
clinic
rout
adequ
induc
immun
respons
inject
site
reaction
evalu
studi
util
relev
rout
administr
mechan
action
vaccin
well
understood
ie
induct
specif
immun
respons
vaccin
antigen
expect
immun
respons
relev
speci
gener
associ
transient
toxic
littl
offtarget
toxic
observ
dose
rang
purpos
identifi
mtd
may
littl
valu
furthermor
doserang
studi
expect
conduct
accord
indian
guidanc
would
requir
test
vaccin
formul
specif
prepar
toxicolog
studi
instead
formul
repres
test
clinic
attempt
perform
dose
rang
identifi
mtd
may
requir
either
administ
dose
volum
exceed
accept
anim
welfar
perspect
formul
vaccin
concentr
allow
administr
higher
dose
maintain
accept
dose
volum
case
unaccept
dose
volum
administr
effect
inject
site
like
observ
base
mechan
trauma
alon
potenti
mask
reactogen
result
vaccin
vaccin
formul
higher
concentr
materi
would
longer
repres
clinic
formul
would
make
inject
site
reaction
difficult
interpret
gener
toxic
data
obtain
studi
vaccin
administ
dose
level
concentr
far
exceed
clinic
dose
may
mislead
indic
safeti
vaccin
instead
use
multipl
predict
human
dose
vaccin
candid
toxicolog
studi
routin
done
small
molecul
test
human
iii
vaccin
equival
dose
use
clinic
formul
consid
regulatori
author
adequ
establish
safeti
margin
vaccin
base
differ
bodi
weight
human
anim
model
exampl
full
human
dose
ml
administ
kg
rat
provid
approxim
safeti
margin
kg
human
case
infant
vaccin
discrep
guidelin
differ
countri
pose
great
challeng
global
vaccin
manufactur
conceiv
futur
interact
review
committe
genet
manipul
rcgm
drug
control
gener
india
dcgi
would
facilit
discuss
address
point
rais
differ
expect
toxicolog
studi
vaccin
possibl
align
recommend
guidelin
addit
consider
manufactur
awar
countryspecif
requir
attempt
initi
clinic
studi
file
submiss
regist
vaccin
alreadi
market
countri
guidelin
nonclin
evalu
vaccin
place
toxicolog
studi
vaccin
candid
requir
prior
entri
clinic
trial
countri
eg
japan
russia
may
requir
thorough
review
avail
anim
data
even
tradit
nonclin
toxic
data
includ
clinic
trial
applic
cta
inform
deem
insuffici
request
may
made
conduct
routin
nonclin
toxic
studi
prior
initi
clinic
studi
andor
worldwid
market
applic
wma
submiss
fulfil
regulatori
expect
outlin
current
guidelin
light
exist
clinic
data
proven
safeti
record
human
vaccin
market
difficult
justifi
retroact
conduct
nonclin
toxicolog
studi
vaccin
import
vaccin
sponsor
clearli
commun
reason
lack
toxicolog
data
vaccin
author
market
primarili
western
countri
year
prior
requir
nonclin
toxic
test
vaccin
emphas
exist
clinic
data
relev
evid
vaccin
safeti
moreov
carri
toxicolog
studi
vaccin
safeti
administ
million
human
would
counter
current
worldwid
expect
reduct
anim
use
vaccin
develop
begin
nonclin
studi
immunogen
evalu
indic
potenti
efficaci
human
accord
current
regulatori
requir
vaccin
candid
determin
suitabl
clinic
test
nonclin
toxic
studi
conduct
support
clinic
studi
prior
conduct
nonclin
toxic
studi
vaccin
subject
batteri
test
ensur
materi
meet
minimum
specif
characterist
mass
ident
puriti
potenc
steril
safeti
main
portion
nonclin
toxic
studi
preced
introduct
human
clinic
trial
studi
may
conduct
support
later
trial
earlier
trial
ongo
studi
design
casebycas
basi
minimum
requir
may
appli
vaccin
conduct
toxic
studi
particular
vaccin
vaccin
type
indic
must
taken
consider
select
speci
strain
anim
use
formul
administ
rout
method
vaccin
administ
number
dose
dose
level
detail
incorpor
overal
design
studi
appli
type
studi
conduct
nonclin
clinic
test
conduct
vaccin
determin
safe
efficaci
human
market
author
obtain
product
qualiti
character
safeti
test
conduct
lot
part
releas
procedur
prior
human
use
purpos
nonclin
toxic
studi
identifi
potenti
target
organ
effect
may
predict
human
toxic
guidelin
state
toxic
studi
design
match
clinic
regimen
close
possibl
regard
dose
level
rout
frequenc
administr
deliveri
devic
plan
clinic
use
toxic
assess
may
standalon
includ
studi
incorpor
toxic
endpoint
includ
evalu
local
toler
toxic
evalu
follow
singl
repeat
dose
separ
studi
may
conduct
purpos
evalu
may
perform
follow
first
dose
repeatdos
studi
except
eg
immunogen
assay
may
qualifi
valid
health
author
requir
studi
support
clinic
studi
conduct
good
laboratori
practic
glp
condit
gener
studi
design
revers
may
monitor
ie
inclus
recoveri
group
guidelin
indic
materi
evalu
nonclin
studi
repres
clinic
formul
possibl
actual
clinic
materi
manufactur
current
good
manufactur
practic
cgmp
use
howev
accept
use
nongmp
materi
test
meet
minimum
releas
specif
includ
potenc
steril
puriti
ident
endotoxin
bioburden
well
stabil
addit
paramet
use
character
vitro
version
test
prefer
case
anim
test
requir
eg
gener
safetyabnorm
toxic
rabbit
pyrogen
test
test
stabil
typic
includ
conduct
vitro
andor
vivo
test
use
releas
predefin
interv
month
also
use
determin
shelflif
particular
product
clinic
develop
formul
chang
expect
health
author
natur
chang
evalu
determin
addit
nonclin
test
would
requir
regulatori
author
recogn
one
relev
anim
speci
gener
suffici
relev
minim
defin
capabl
develop
immun
respons
vaccin
ideal
sensit
biolog
effect
pathogen
organ
toxin
vaccin
design
protect
anim
model
select
toxic
studi
evalu
nonclin
immunogen
studi
may
prudent
confirm
speci
relev
use
pilot
immunogen
studi
select
toxic
model
use
anticip
clinic
dose
prior
conduct
glp
toxic
studi
outbr
anim
proven
health
statu
use
situat
one
speci
requir
includ
mechan
protect
induc
well
understood
iii
vaccin
speciesor
strainspecif
differ
pharmacodynam
effect
vaccin
health
author
recommend
ten
anim
per
gender
use
routin
rodent
fewer
nonrod
nonhuman
primat
rabbit
recoveri
group
fewer
anim
use
interim
evalu
may
justifi
per
guidelin
rodent
week
age
studi
start
rabbit
month
age
typic
singl
dose
level
evalu
nonclin
studi
match
highest
dose
use
clinic
studi
per
guidanc
health
author
feasibl
base
anim
welfar
concern
dose
level
provid
safeti
margin
dose
may
select
exce
human
dose
mgkg
basi
elicit
immun
respons
although
evalu
doserespons
identif
mtd
requir
toxic
observ
recommend
regulatori
author
lower
dose
evalu
accord
guidelin
number
dose
administ
test
anim
equal
greater
number
dose
propos
human
typic
one
dose
anticip
clinic
administ
anim
ie
dose
given
clinic
dose
interv
may
quit
extend
ie
month
frequenc
dose
anim
studi
may
shorten
rel
propos
clinic
trial
base
kinet
immun
respons
rather
match
clinic
dose
schedul
end
dose
typic
administ
defin
interv
week
health
author
recommend
repeatdos
studi
conduct
even
case
vaccin
administ
singl
dose
clinic
howev
singl
dose
studi
may
justifi
case
exampl
vaccineinduc
antibodi
expect
neutral
live
viru
vector
therebi
limit
express
protein
interest
immun
respons
may
affect
speciesspecif
protein
vaccin
formul
guidelin
indic
rout
administr
match
plan
use
clinic
studi
addit
rout
administr
may
use
unexpect
toxic
observ
use
select
rout
neg
control
group
includ
appropri
activ
control
group
ie
formul
without
antigen
may
includ
histor
data
particular
adjuv
excipi
avail
recoveri
group
includ
investig
revers
advers
effect
screen
possibl
delay
advers
effect
routin
paramet
indic
nonclin
guidelin
clinic
sign
bodi
weight
food
consumpt
serum
biochemistri
hematolog
gross
histomorpholog
examin
includ
toxic
studi
order
evalu
toxic
candid
vaccin
emphasi
immun
paramet
local
inflammatori
reaction
effect
drain
lymph
node
induct
immun
system
biomark
cytokin
chemokin
data
collect
treatment
period
day
follow
first
last
dose
end
recoveri
phase
health
author
requir
immun
respons
vaccin
measur
confirm
relev
anim
model
patholog
evalu
includ
emphasi
inject
site
immun
organ
drain
distant
lymph
node
extent
patholog
evalu
iii
vaccin
determin
amount
nonclin
clinic
data
avail
candid
vaccin
andor
adjuvantexcipi
present
formul
given
vaccin
administ
via
either
intramuscular
subcutan
rout
common
advers
find
local
reactogen
order
predict
likelihood
reaction
clinic
studi
regulatori
guidelin
indic
evalu
local
toler
includ
histopatholog
site
inject
includ
either
part
toxic
studi
standalon
studi
local
reactogen
anticip
unaccept
level
observ
addit
studi
design
evalu
mechan
toxic
may
need
although
immun
respons
candid
vaccin
gener
part
mechan
action
may
circumst
immun
respons
may
result
toxic
eg
autoimmun
due
similar
vaccin
antigen
host
protein
precipit
immun
complex
exacerb
diseas
hypersensit
case
addit
studi
design
evalu
mechan
toxic
may
requir
health
author
given
complex
studi
question
predict
natur
endpoint
actual
patholog
vaccin
anticip
caus
effect
studi
care
mani
vaccin
indic
use
childhood
would
therefor
requir
nonclin
development
toxic
studi
howev
unless
sound
scientif
argument
made
indic
studi
unnecessari
regul
requir
prevent
therapeut
vaccin
infecti
diseas
indic
women
childbear
potenti
pregnant
women
evalu
nonclin
studi
purpos
studi
assess
advers
effect
pregnanc
statu
andor
develop
embryofetu
result
matern
immun
modul
inher
biolog
activ
vaccin
antigen
andor
constitu
vaccin
product
eg
adjuv
excipi
development
toxic
studi
may
also
trigger
find
repeatdos
toxic
studi
indic
effect
reproduct
organ
distributionpersist
plasmid
viral
vectorbas
vaccin
gonad
tissu
health
author
indic
need
fertil
studi
evalu
casebycas
basi
accord
regulatori
guidelin
case
vaccin
either
similar
combin
vaccin
development
toxic
studi
alreadi
perform
addit
development
toxic
studi
may
need
signific
chang
made
compon
new
adjuv
excipi
concern
exist
regard
increas
toxic
upon
mixtur
individu
compon
case
combin
vaccin
time
development
toxic
studi
differ
variou
popul
regulatori
author
recommend
data
nonclin
development
toxic
studi
vaccin
indic
use
pregnant
women
avail
prior
enrol
pregnant
women
clinic
trial
women
childbear
potenti
may
enrol
clinic
trial
prior
conduct
nonclin
development
toxic
studi
provid
precaut
taken
avoid
pregnanc
trial
popul
singl
development
toxic
studi
conduct
typic
concurr
phase
iii
clinic
trial
time
may
vari
depend
countri
clinic
studi
conduct
guidelin
detect
toxic
reproduct
medicin
product
toxic
male
fertil
ich
use
refer
tool
given
complex
evalu
vaccin
compon
test
paradigm
distinct
vaccin
per
guidelin
nonclin
test
strategi
describ
ich
may
need
alter
particular
vaccin
studi
adequ
evalu
previou
clinic
experi
includ
data
immunogen
studi
pregnant
women
taken
account
design
nonclin
studi
data
may
help
risk
assess
may
preclud
need
nonclin
studi
data
previou
nonclin
studi
may
use
aid
speci
dose
select
development
toxic
studi
well
interpret
studi
result
regulatori
agenc
recommend
earli
dialogu
gain
concurr
plan
development
toxic
evalu
gener
outlin
studi
endpoint
avail
typic
model
includ
rat
rabbit
mous
one
speci
gener
suffici
nonhuman
primat
use
case
altern
avail
repeatdos
toxic
studi
regulatori
guidelin
indic
anim
model
chosen
relev
ie
abil
mount
immun
respons
gener
speci
use
repeatdos
development
toxic
studi
addit
abil
test
anim
mount
immun
respons
also
import
evalu
matern
antibodi
transfer
measur
vaccineinduc
antibodi
cord
fetal
blood
verifi
exposur
embryo
fetu
matern
antibodi
given
import
immun
respons
establish
relev
preclin
model
expect
inform
onset
durat
antibodi
respons
obtain
guidelin
indic
sampl
collect
prior
exposur
vaccin
studi
day
cesarian
section
end
wean
period
mani
way
evalu
immun
respons
antibodi
measur
routin
use
marker
vaccineinduc
effect
repeatdos
toxic
studi
nonpregn
anim
may
use
purpos
unless
evid
suggest
immun
respons
differ
pregnant
anim
repeatdos
toxic
studi
guidelin
dictat
rout
administr
mimic
clinic
rout
maxim
human
dose
administ
materi
use
ident
repres
final
clinic
formul
administr
full
human
dose
feasibl
dose
exce
full
human
dose
mgkg
basi
elicit
immun
respons
use
dose
frequenc
depend
onset
durat
immun
respons
particular
vaccin
studi
gener
episod
dose
recommend
regulatori
author
indic
case
lack
iii
vaccin
relev
anim
model
hinder
assess
immun
respons
development
toxic
studi
may
still
valu
respect
potenti
embryofet
toxic
effect
vaccin
componentsformul
prevent
therapeut
vaccin
safeti
concern
gener
relat
develop
growth
embryo
fetu
therefor
primari
focu
detect
advers
effect
pregnantlact
femal
develop
embryo
fetu
offspr
follow
exposur
pregnant
femal
vaccin
implant
end
pregnanc
anim
routin
expos
vaccin
premat
stage
period
implant
closur
hard
palat
end
gestat
evalu
effect
organogenesi
stage
c
e
per
ich
premat
booster
dose
administr
need
ensur
exposur
embryo
fetu
vaccineinduc
immun
respons
well
compon
vaccin
formul
postnat
followup
birth
wean
recommend
evalu
normal
growth
bodi
weight
gain
suckl
activ
viabil
end
one
subgroup
femal
subject
cesarian
section
allow
uterin
fetal
examin
second
subgroup
allow
litter
postnat
followup
offspr
suffici
number
anim
use
allow
evalu
least
anim
per
group
alloc
anim
cesarian
litter
subgroup
control
group
pb
other
design
evalu
certain
aspect
formul
adjuv
excipi
includ
guidelin
indic
typic
endpoint
provid
data
prenat
postnat
develop
includ
matern
function
describ
ich
includ
routin
toxic
endpoint
evalu
includ
clinic
observ
includ
data
gener
appear
bodi
weight
local
toler
food
consumpt
well
studyspecif
endpoint
durat
pregnanc
abort
prematur
deliveri
parturit
cesarian
section
group
matern
observ
includ
necropsi
macroscop
evalu
well
record
number
distribut
corpora
lutea
implant
site
viabl
nonviabl
fetus
earli
late
resorpt
well
gross
evalu
placenta
fetal
examin
cesarian
group
includ
bodi
weight
live
fetus
evalu
viabl
fetus
gross
extern
viscer
skelet
alter
extent
possibl
late
resorpt
nonviabl
fetus
also
examin
gross
extern
alter
gender
fetus
determin
via
intern
evalu
matern
observ
natur
deliveri
group
includ
determin
durat
gestat
paramet
fertil
gestat
live
birth
indic
follow
prewean
period
dam
sacrif
gross
necropsi
thorac
abdomin
pelvic
viscera
may
perform
distribut
implant
site
observ
abnorm
record
guidelin
indic
caus
death
pregnanc
statu
determin
anim
die
sacrif
earli
abort
fetus
andor
deliv
pup
examin
feasibl
offspr
allow
matur
mate
gener
evalu
normal
growth
bodi
weight
gain
nurs
activ
function
observ
evalu
also
conduct
viabil
lactat
indic
record
gender
determin
gross
necropsi
perform
end
studi
pup
sacrif
die
earli
evalu
abnorm
caus
death
appropri
lack
effect
development
toxic
studi
may
predict
human
respons
due
factor
speciesspecif
differ
immun
iii
vaccin
respons
differ
development
time
line
differ
placent
studi
design
optim
predict
valu
caus
concern
exist
vaccin
studi
may
immunotox
studi
conduct
indic
advers
effect
may
observ
one
could
consid
paramet
may
incorpor
studi
design
evalu
lymphocyt
subset
specif
biomark
regulatori
guidelin
gener
requir
genotox
carcinogen
studi
vaccin
base
limit
exposur
vaccin
antigen
follow
administr
intermitt
administr
signific
interv
dose
limit
number
repeat
administr
lifetim
individu
receiv
vaccin
except
may
case
novel
compon
adjuv
excipi
includ
vaccin
formul
determin
genotox
studi
requir
test
mutat
chromosom
damag
conduct
prior
introduct
vaccin
human
full
batteri
test
may
conduct
parallel
clinic
trial
per
guidanc
genotox
test
data
interpret
pharmaceut
intend
human
use
ich
vaccin
guidelin
indic
safeti
pharmacolog
studi
need
data
nonclin
clinic
studi
suggest
vaccin
may
affect
physiolog
paramet
central
nervou
system
cn
respiratori
cardiovascular
cv
renal
function
one
notabl
except
japanes
guidanc
state
safeti
pharmacolog
studi
requir
vaccin
novel
well
previous
market
howev
guidanc
indic
standalon
safeti
pharmacolog
studi
may
reduc
elimin
specif
endpoint
includ
repeatdos
toxic
studi
furthermor
base
author
person
experi
requir
nonclin
safeti
pharmacolog
studi
may
also
limit
omit
safeti
pharmacolog
endpoint
eg
ecg
evalu
includ
part
clinic
evalu
oversea
prior
conduct
clinic
studi
japan
event
safeti
pharmacolog
studi
requir
given
repeatdos
toxic
studi
typic
conduct
rat
rabbit
assess
cv
paramet
part
gener
toxic
studi
well
establish
rare
feasibl
therefor
practic
separ
safeti
pharmacolog
studi
would
conduct
purpos
highli
desir
perform
safeti
pharmacolog
studi
speci
use
gener
toxicolog
studi
order
put
toxic
respons
perspect
studi
data
possibl
eg
toxicolog
speci
rabbit
studi
nonhuman
primat
relev
speci
would
need
conduct
design
safeti
pharmacolog
studi
vaccin
consid
casebycas
basi
gener
descript
design
studi
may
found
safeti
pharmacolog
studi
human
pharmaceut
ich
health
author
recogn
tradit
pharmacokinet
evalu
requir
vaccin
exampl
formul
contain
novel
adjuv
altern
rout
administr
use
local
deposit
distribut
studi
conduct
evalu
retent
time
site
administr
determin
vaccin
compon
distribut
respect
purpos
adjuv
boost
immun
respons
antigen
contain
vaccin
given
regulatori
public
scrutini
surround
use
adjuv
import
provid
rational
need
adjuv
support
evid
relev
anim
model
eg
charact
immun
respons
protect
lethal
challeng
pathogen
organ
inform
literatur
sinc
adjuv
design
elicit
type
durat
immun
respons
separ
immunogen
toxicolog
evalu
conduct
per
regulatori
guidelin
pharmacokinet
studi
requir
toxic
data
exist
full
toxicolog
evalu
adjuv
alon
conduct
similar
new
chemic
entiti
one
adjuv
use
evalu
alon
combin
conduct
though
speci
select
studi
ideal
use
proofofconcept
speci
select
depend
upon
antigen
adjuv
combin
potenti
speci
specif
associ
adjuv
adjuvantalon
studi
evalu
local
toler
induct
hypersensit
anaphylaxi
well
pyrogen
recommend
adjuv
administ
interv
reflect
propos
clinic
use
system
toxic
evalu
includ
full
necropsi
tissu
collect
histopatholog
evalu
includ
dose
respons
highest
dose
may
select
base
expect
clinic
use
rather
establish
mtd
endpoint
includ
outlin
guidelin
evalu
new
chemic
entiti
adjuv
intend
use
pregnant
women
women
childbear
potenti
reproduct
toxic
studi
conduct
dose
regimen
reflect
intend
clinic
plan
vaccin
administ
prior
pregnanc
adjuv
biolog
natur
treat
biotechnolog
product
therefor
requir
genotox
test
per
ich
synthet
adjuv
subject
standard
batteri
genet
toxic
test
per
ich
health
author
requir
clinic
formul
contain
adjuv
antigen
evalu
ensur
combin
compat
demonstr
consist
adsorpt
exert
synergist
effect
toxic
character
immun
respons
also
includ
dose
respons
adjuv
antigen
well
compar
studi
design
evalu
immun
respons
vaccin
absenc
adjuv
per
regulatori
guidelin
addit
evalu
manner
similar
adjuv
absenc
toxic
data
full
toxic
studi
conduct
new
chemic
entiti
final
clinic
formul
evalu
ensur
compat
etc
guidelin
dictat
vaccin
formul
deliveri
devic
intend
clinic
studi
use
nonclin
toxic
studi
possibl
exampl
lack
appropri
anim
model
pilot
studi
conduct
develop
model
prior
conduct
nonclin
toxic
studi
select
appropri
anim
model
vaccin
deliv
altern
rout
administr
nonparenter
rout
oral
intraderm
etc
health
author
recommend
anatomi
anim
model
particular
rel
site
administr
taken
consider
one
may
ensur
anim
properli
expos
vaccin
appropri
anim
model
avail
may
necessari
employ
sever
studi
differ
anim
model
adequ
evalu
toxic
dose
administ
may
differ
parenter
altern
rout
identifi
therefor
regulatori
guidelin
indic
dose
rang
studi
may
requir
determin
appropri
dose
dose
volum
administ
via
altern
rout
chosen
addit
endpoint
typic
includ
routin
toxic
studi
see
previou
section
toxic
assess
recommend
addit
evalu
consid
determin
whether
administr
would
affect
specif
target
organ
associ
particular
rout
administr
lung
inhal
vaccin
vaccin
administ
via
altern
rout
may
affect
immun
system
differ
result
immun
respons
involv
protect
antibodi
andor
cellular
immun
therefor
guidelin
indic
addit
serolog
assay
test
tand
bcell
respons
cytokin
product
consid
assay
assess
local
system
respons
distant
site
may
also
need
develop
addit
safeti
concern
address
routin
vaccin
gener
special
consider
taken
account
specif
type
vaccin
live
attenu
dna
viral
vector
combin
vaccin
live
attenu
vaccin
contain
version
live
viru
weaken
caus
seriou
diseas
peopl
healthi
immun
system
exampl
live
attenu
vaccin
includ
measl
mump
rubella
vaccin
mmr
varicella
chickenpox
vaccin
guidelin
indic
nonclin
evalu
live
attenu
vaccin
includ
assess
degre
stabil
attenu
assay
implement
distinguish
attenu
fulli
virul
ideal
partial
virul
strain
assess
revers
product
process
also
design
way
assess
stabil
attenu
likelihood
exchang
genet
inform
nonvaccin
strain
also
determin
wildtyp
viru
neurotrop
vaccin
passag
neural
tissu
health
author
requir
evalu
neurovirul
nonclin
develop
includ
model
capabl
distinguish
wildtyp
fulli
partial
attenu
strain
small
anim
model
may
accept
purpos
provid
suscept
wildtyp
viru
program
includ
live
attenu
vaccin
base
genet
modifi
organ
also
includ
environment
risk
assess
includ
possibl
shed
vaccin
organ
follow
administr
plasmid
dna
vaccin
defin
purifi
plasmid
prepar
contain
one
dna
sequenc
capabl
induc
andor
promot
immun
respons
pathogen
guidelin
indic
nonclin
toxic
studi
dna
vaccin
follow
glp
guidelin
conduct
prior
initi
phase
clinic
studi
nonclin
toxic
studi
vaccin
care
consid
base
productspecif
characterist
plan
clinic
studi
previou
experi
similar
construct
gener
studi
conduct
per
recommend
guidelin
nonclin
evalu
vaccin
per
guidelin
dna
vaccin
sever
potenti
safeti
issu
specif
administr
plasmid
dna
human
inject
dna
taken
cell
host
may
integr
host
chromosom
caus
insert
mutagen
event
ii
longterm
express
foreign
antigen
may
result
undesir
immunopatholog
reaction
iii
use
gene
encod
cytokin
costimulatori
molecul
may
pose
addit
risk
iv
antibodi
inject
dna
may
form
may
contribut
toward
undesir
autoimmun
reaction
v
express
antigen
may
biolog
activ
vi
express
gene
sequenc
antibiot
resist
mammalian
bacteri
cell
may
pose
risk
therefor
addit
studi
design
evalu
system
toxic
iii
vaccin
local
reactogen
regulatori
author
requir
studi
design
evalu
plasmid
biodistribut
persist
integr
conduct
use
sensit
nucleic
acid
detect
techniqu
quantit
polymeras
chain
reaction
qpcr
base
assay
risk
associ
dna
integr
includ
tumorigenesi
chromosom
instabl
evalu
serv
determin
tissu
distribut
follow
administr
potenti
vector
integr
host
genom
panel
tissu
includ
blood
heart
brain
liver
kidney
bone
marrow
ovariestest
lung
drain
lymph
node
spleen
muscl
subcuti
site
administr
evalu
given
plasmid
encod
differ
antigen
behav
similarli
vivo
health
author
may
waiv
requir
biodistribut
studi
vaccin
studi
alreadi
conduct
accept
biodistributionintegr
profil
evalu
conduct
earli
late
time
point
possibl
distribut
express
germlin
cell
must
evalu
unless
otherwis
justifi
persist
plasmid
gonad
tissu
time
would
trigger
addit
evalu
tissu
ova
sperm
cell
well
studi
determin
effect
fertil
gener
reproduct
function
embryofet
perinat
toxic
studi
may
also
requir
women
childbear
potenti
expos
product
dna
vaccin
util
novel
vector
formul
method
deliveri
rout
administr
modif
expect
significantli
impact
cellular
uptak
andor
biodistribut
may
requir
studi
regulatori
agenc
recommend
input
solicit
specif
need
prior
conduct
studi
integr
studi
conduct
determin
plasmid
persist
level
greater
copi
per
host
dna
studi
termin
addit
dna
vaccin
encod
multipl
antigen
requir
immun
respons
gener
repres
subset
encod
antigen
evalu
addit
evalu
cytokin
vaccin
gene
encod
immunomodulatori
case
sequenti
immun
use
one
type
vaccin
conduct
primeboost
regimen
includ
base
input
regulatori
agenc
specif
studi
evalu
autoimmun
recommend
thorough
evalu
welfar
anim
includ
nonclin
toxic
studi
biolog
produc
use
recombin
dna
technolog
activ
ingredi
radic
alter
natur
substanc
nonclin
test
may
includ
carcinogen
teratogen
effect
fertil
case
conduct
casebycas
basi
input
regulatori
agenc
per
ema
guidelin
viral
vector
vaccin
live
recombin
vector
vaccin
live
virus
express
heterolog
antigen
viral
vector
may
replicationdefect
replicationcompet
exampl
viral
vector
util
purpos
pox
virus
adenovirus
alphavirus
measl
viru
yellow
fever
viru
vesicular
stomat
viru
antigen
may
viral
bacteri
parasit
origin
gener
deriv
infecti
agent
effect
vaccin
exist
human
immunodefici
viru
hiv
malaria
dengu
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
ebola
viru
immun
respons
elicit
live
viral
iii
vaccin
vector
vaccin
specif
heterolog
antigen
antigen
vector
evalu
immun
respons
overal
vector
vaccin
requir
health
author
addit
human
virul
vaccin
may
predict
known
virul
vector
alon
studi
appropri
anim
model
conduct
evalu
virul
nonclin
toxic
studi
live
viru
vector
vaccin
conduct
accord
ema
guidelin
nonclin
evalu
vaccin
except
regard
speci
relev
regulatori
guidelin
indic
prefer
use
speci
anim
model
diseas
establish
evalu
immun
respons
vaccin
consider
given
preexist
immun
nonprotect
immun
vector
andor
heterolog
antigen
immunogen
evalu
also
includ
quantit
well
qualit
data
character
humor
cellmedi
innat
immun
respons
appropri
intend
protect
antigen
well
antigen
vector
select
group
evalu
nonclin
toxic
studi
requir
group
consist
vector
alon
includ
immun
respons
vector
found
interfer
respons
subsequ
administr
vaccin
singledos
studi
may
justifi
biodistribut
studi
also
includ
toxic
evalu
live
recombin
vaccin
guidelin
indic
reproduct
toxic
studi
consid
case
vaccin
may
administ
pregnant
women
biodistribut
studi
show
replic
reproduct
organ
reproduct
toxic
studi
requir
vaccin
administ
sensit
period
fetal
develop
combin
vaccin
inact
diphtheria
tetanu
pertussi
dptt
live
mmr
avail
decad
proven
safeti
record
new
combin
exist
novel
vaccin
must
evalu
nonclin
effect
immunogen
adsorpt
aluminum
adjuv
stabil
health
author
requir
qualiti
immun
respons
evalu
well
potenti
interfer
incompat
antigen
thorough
evalu
would
includ
comparison
combin
product
individu
compon
requir
studi
design
specif
evalu
safeti
combin
product
determin
casebycas
basi
gener
conduct
known
theoret
risk
associ
combin
guidelin
indic
nonclin
test
also
consid
case
novel
singlecompon
vaccin
develop
previous
licens
combin
vaccin
begin
approxim
nonclin
test
guidelin
implement
vaccin
first
global
document
guidelin
nonclin
evalu
vaccin
still
consid
gold
standard
comprehens
document
provid
detail
anim
model
studi
design
endpoint
altern
method
addit
guidelin
mani
guidanc
document
also
avail
outlin
iii
vaccin
regulatori
expect
tradit
vaccin
well
particular
type
vaccin
administ
pregnant
women
women
childbear
potenti
adjuv
dna
viral
vector
vaccin
combin
vaccin
highli
desir
vaccin
manufactur
appli
strategi
method
nonclin
test
vaccin
era
global
develop
market
howev
guidelin
major
countri
provid
fairli
standard
recommend
manufactur
also
awar
countryspecif
guidanc
document
may
requir
addit
differ
studi
expect
broadli
defin
requir
toxicolog
program
vaccin
